CD73

The objective of this program is to design and synthesize small molecule candidates that could block the activity of CD73, a novel therapeutic target in immuno-oncology. Presently, the field of immunotherapy represents considerable value for pharmaceutical companies. Besides the development of therapeutics, this program also aims to determine which patient population(s) would most benefit from a treatment aimed at blocking CD73. This program is a collaboration between Dr. John Stagg (Centre de recherche du Centre hospitalier de l’Université de Montréal), the winner of our 2013 KNOCK OUT^TM EVENT, and NuChem Therapeutics.